Patient Perception Study for AL-4943A

Phase 4

Completed

• Conditions: Allergic Conjunctivitis
• Interventions: Drug: AL-4943A

• Registration Number: NCT01294969
• Lead Sponsor: Alcon Research

Brief Summary

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2010-09
• Study First Submitted: 2011-02-10
• Study First Submitted QC: 2011-02-11
• Study First Posted: 2011-02-14
• Status Verified: 2011-10
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Last Update Submitted: 2016-12-15
• Last Update Posted: 2016-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• History of allergic conjunctivitis within last 24 months
• Active signs and symptoms of ocular allergies

Read More

Exclusion Criteria

• Severe or serious ocular condition, ocular surgical intervention, ocular infection

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AL-4943A	AL-4943A	One drop per day in both eyes

Primary Outcome Measures

Name	Time	Method
Overall Patient satisfaction	7 days

Trial Locations

Locations (1)

Alcon Korea Ltd.; 🇰🇷 Seoul, Korea, Republic of